Have any questions?706-721-6582orcts@augusta.edu
- S1605; Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Clinical Trial
S1605; Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
The purpose of this study is to test the good and bad effects of the investigational drug atezolizumab in stopping non-muscle invasive bladder cancer from coming back and progressing to muscle invasive bladder cancer. Atezolizumab is not approved by the FDA for treatment of this type of cancer.
Eligibility Criteria
- - Recurrent bladder cancer - 18 years of age or older
RESEARCH. INNOVATION. DISCOVERY.